Context: NaPi-IIa, encoded by SLC34A1, is a key phosphate transporter in the mammalian proximal tubule and plays a cardinal role in renal phosphate handling. NaPi-IIa impairment has been linked to various overlapping clinical syndromes, including hypophosphatemic nephrolithiasis with osteoporosis, renal Fanconi syndrome with chronic kidney disease, and, most recently, idiopathic infantile hypercalcemia and nephrocalcinosis.
studies indicate that NaPi-IIa mediates the bulk of renal phosphate reabsorption (2, 3) , data derived from human Mendelian disorders of renal phosphate handling consistently link NaPi-IIc disruption with substantial renal phosphate wasting (4, 5) , whereas NaPi-IIa impairment is associated with marked phenotypic heterogeneity and with a variable impact on renal phosphate handling.
To date, at least three different human phenotypes have been linked with NaPi-IIa variation. The first of these is hypophosphatemic nephrolithiasis with osteoporosis type 1 (MIM 612286), an autosomal dominant trait associated with hyperphosphaturia, nephrolithiasis, and bone demineralization. Heterologous expression experiments in Xenopus laevis oocytes demonstrated functional impairment of identified NaPi-IIa variants, combined with their dominant negative effect over the wild-type (WT) allele (6) . However, these findings could not be reproduced in subsequent studies (7, 8) . Nevertheless, recent genomewide association studies demonstrate a link between SLC34A1 gene locus variants and increased susceptibility to calcium nephrolithiasis and renal phosphate wasting (9) (10) (11) . Taken together, this portrays a still confusing picture regarding the role of heterozygous NaPi-IIa variants in the pathogenesis of renal phosphate wasting and calcium nephrolithiasis.
The second disorder is renotubular Fanconi syndrome type 2 (FRTS2; MIM 613388), a rare autosomal recessive disorder of proximal tubulopathy, hypophoshatemic rickets, and progressive renal impairment, associated with the first reported homozygous loss-of-function mutation in SLC34A1. To our knowledge, the disorder was described first by us in two adult siblings from a consanguineous Israeli-Arab family (12) , following an earlier clinical report of these patients (13) . Full phenotypic assessment during infancy and early childhood was unavailable, and the patients presented in adolescence with hypophosphatemic rickets, hypercalciuria, elevated 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ] levels, normal parathyroid hormone (PTH), normal glomerular filtration rate (GFR), and renal Fanconi syndrome. Clinical reassessment after two decades revealed persistent proximal tubulopathy, normocalcemia, normocalciuria, renal Pi wasting with hypophosphatemic bone disease, and stage II to III chronic kidney disease (CKD). Molecular analysis revealed a homozygous in-frame inserted duplication in NaPi-IIa (p.I154_V160dup-NaPi-IIa) adjacent to a highly conserved domain within the NaPi-IIa protein.
The mutation segregated with the phenotype in an autosomal recessive inheritance pattern. Functional studies showed complete loss of phosphate transport by the mutant transporter, secondary to a trafficking defect (12) . To date, no additional patients with NaPiIIa disruption and renal Fanconi syndrome have been reported, and the pathogenesis of proximal tubular impairment and reduced kidney function in association with NaPi-IIa disruption is unresolved.
The third clinical syndrome is idiopathic infantile hypercalcemia (IIH), manifested by infantile hypercalcemia, nephrocalcinosis, and increased sensitivity to prophylactic vitamin D supplementation (14, 15 (16) . More recently, biallelic mutations in SLC34A1 were identified in infants with IIH and renal phosphate wasting, with no CYP24A1 mutations, and designated as infantile hypercalcemia 2 (HCINF2; MIM 616963) (17, 18) . During follow-up, most patients exhibit improvement of hypercalcemia, persistently mild renal phosphate wasting, and no evidence of rickets, proximal tubulopathy, or CKD (18) .
In a recent report (19) , molecular analysis in an adolescent male with congenital nephrocalcinosis, CKD, and no evidence of proximal tubulopathy revealed a homozygous missense mutation in SLC34A1, associated with partially impaired NaPi-IIa trafficking and activity.
Taken together, accumulating data suggest considerable intra-and interindividual phenotypic heterogeneity among patients with NaPi-IIa dysfunction, with an apparent age-dependent effect. However, the contributing factors of this clinical diversity are largely unknown, and longitudinal data regarding the natural history of various phenotypic features are lacking.
In this study, we describe two apparently unrelated infants of Israeli and Turkish descent who presented with IIH and early onset partial proximal tubular impairment, secondary to the previously reported p.I154_V160dup mutation in NaPi-IIa, which was found to be associated with renal Fanconi syndrome and CKD (FRTS2) at an older age.
Patients and Methods

Patients
We describe two apparently unrelated male infants of Israeli and Turkish descent who presented with hypercalemia, nephrocalcinosis, and partial proximal tubular impairment.
The study protocol, including clinical, biochemical, and genetic analyses, was approved by institutional ethics review committees, and written informed consent was obtained from all participants and their legal guardians.
Phenotypic analysis
Serum and urine biochemical analyses were performed using standard laboratory protocols. Urinalyses were performed on spot urine samples during infancy and on 24-hour urine collections during childhood. Plasma C-terminal fibroblast growth factor-23 (FGF-23) levels were determined using a commercial ELISA kit (TECOmedical AG, Sissach, Switzerland). Tubular reabsorption of phosphate per deciliter glomerular filtrate (TP/ GFR) and urinary uric acid/dL GFR were calculated as previously described (20, 21) .
Genetic analysis
Genomic DNA was extracted from peripheral blood lymphocytes using a standard technique (22) . Conventional Sanger sequencing of the entire coding regions and intron-exon boundaries of SLC34A1 (GenBank accession number NC_000005.1) and CYP24A1 (GenBank accession number NC_000020.11) were performed on genomic DNA, as previously described (12, 23) .
Haplotype analysis in affected infants was performed by single-nucleotide polymorphism (SNP) microarray genotyping (CytoScan 750K Array; Affymetrix, Santa Clara, CA), using the Chromosome Analysis Suite software (Affymetrix) on human genome assembly hg19.
For exome sequencing, library preparation and exome enrichment were performed using Illumina' In vitro localization and endoplasmic reticulum analysis experiments Standard protocols were followed for generation of WT and mutant SLC34A1 plasmid constructs, expression in various cell lines, localization experiments, endoglycosidase H (Endo H) and peptide/N-glycosidase F (PNGase F) digestion analysis, proteasomal inhibition assays, and endoplasmic reticulum (ER) stress marker analyses (Supplemental Appendix).
Results
Clinical and genetic analysis
Patient I
A 3.5-month-old male infant was referred for evaluation of medullary nephrocalcinosis and mild hypercalcemia. The patient is the second child of healthy consanguineous parents of Israeli-Arab descent (Fig. 1a) . A maternal grandmother and her sibling were previously described as having FRTS2, in association with the p.I154_V160dup loss-of-function mutation in NaPi-IIa (12) . Previous family screening identified the patient's mother as a heterozygous carrier of the p.I154_V160dup mutation, but the father refused premarital genetic counseling. An 18-month-old female sibling is reported to be healthy and was not brought for clinical evaluation.
The patient was born after an uneventful pregnancy and delivery, with a birth weight of 3.8 kg. Routine prenatal ultrasound examination was normal. He was fed with a combination of breast milk and standard infant formula and received routine prophylactic vitamin D supplementation (400 IU/d) since birth.
Physical examination was unremarkable, with no dysmorphic features, skeletal deformities, or signs of overt rickets, and his growth was within normal range [weight, 6.8 kg, 0.26 standard deviation score (SDS); length, 64 cm, 0.67 SDS; head circumference, 42 cm, 0 SDS].
Laboratory evaluation at presentation (Table 1) indicated mild hypercalcemia, borderline hypophosphatemia, appropriately low intact PTH for serum calcium level, and elevated serum 1,25(OH) 2 D 3 . Urinalysis excluded hypercalciuria or generalized proximal tubulopathy but revealed borderline low TP/GFR for age, indicating mild renal phosphate wasting, and elevated b-2 microglobulin, suggestive of low-molecular-weight (LMW) proteinuria.
Renal sonography showed bilateral medullary nephrocalcinosis, accompanied by normal renal size, contour, and parenchymal thickness, with no evidence of hydroureteronephrosis (Fig. 1c) . Wrist and knee radiographs excluded signs of mineral deficiency bone disease.
Phenotypic assessments of both parents were unremarkable (data not shown).
The patient was managed with cessation of vitamin D supplementation and with increased oral fluid intake. During follow-up, the hypercalcemia resolved, but intermittent hypophosphatemia was noticed, accompanied by decreasing TP/GFR and increasing levels of urinary b-2 microglobulin. The hypophosphatemia was readily corrected with low-dose oral phosphate supplements. Currently, at the age of 3.5 years, the patient maintains normal growth, his GFR is within normal range, and nephrocalcinosis is nonprogressive. 1,25(OH) 2 D 3 levels are persistently elevated, but serum and urine calcium levels are within normal range. Mild renal phosphate wasting and LMW proteinuria persist, accompanied by low-normal plasma levels of FGF-23 but with no additional features of renal Fanconi syndrome. Given the described family history and genetic findings, we performed mutation analysis of SLC34A1 in the affected child and his father and identified the previously reported familial p.I154_V160dup-NaPi-IIa mutation, displayed in a homozygous state in the child and in a heterozygous state in his father (Fig. 1d) .
In view of the intrafamilial phenotypic heterogeneity associated with homozygosity for the p.I154_V160dup-NaPi-IIa mutation and to rule out involvement of another gene in the pathogenesis of renal Fanconi syndrome, we performed whole-exome sequencing in the maternal grandmother and the maternal great-uncle of the patient (both of whom were previously described as having FRTS2), in their mother, and in the currently described infant with IIH. Data analysis did not reveal an additional disease-causing gene variant in segregation with the phenotype of renal Fanconi syndrome in the extended pedigree and excluded a disease-causing recessive mutation in CYP24A1 as a potential cause for IIH in the affected infant (see supplemental results).
Patient II
A 2.5-month-old male infant was referred for evaluation of recurrent urinary tract infections and incidental hypercalcemia. The patient is the second son of consanguineous Turkish parents (Fig. 1b) . Family history was unremarkable, except for past paternal nephrolithiasis.
The patient was born at term, with a birth weight of 3.75 kg, after an uneventful pregnancy and delivery. He was exclusively breastfed and received prophylactic vitamin D supplementation (400 IU/d) since the second week of age, with no history of accidental vitamin D overdose.
Physical examination at presentation was unremarkable, with no evidence of dysmorphic features, skeletal deformities, or growth retardation (weight, 5.3 kg, -0.51 SDS; length, 59 cm, -0.25 SDS).
Laboratory investigation at presentation ( Renal sonography showed bilateral medullary nephrocalcinosis, with no additional abnormalities. A hand-wrist radiograph was interpreted as normal. Echocardiographic assessment was normal, with no evidence for structural abnormalities suggestive of Williams-Beuren syndrome.
The patient was initially managed with cessation of vitamin D supplements and intravenous saline hydration.
Due to persistent hypercalcemia, oral calcium intake was restricted using a low-calcium/vitamin D-free infant formula, and bisphosphonate therapy was added. This regimen resulted in temporary reduction in calcium levels but was followed by episodic hypercalcemia of 10.9 to 11.7 mg/dL and hypophosphatemia of 2.5 to 3.1 mg/dL until spontaneous resolution at ;8 months of age. Thereafter, serum calcium and phosphate levels normalized but were accompanied by decreasing levels of TP/GFR. Currently, at the age of 25 months, he exhibits normal growth, without clinical signs of rickets. Updated biochemical analysis reveals normal serum calcium and phosphate levels, although accompanied by hyperphosphaturia, hyperuricosuria, and LMW proteinuria, suggestive of partial proximal tubulopathy. Renal sonography shows nonprogressive medullary nephrocalcinosis.
With a working diagnosis of IIH and given the genetic heterogeneity of this disorder, we used whole-exome sequencing in the patient, with particular attention to SLC34A1. Sequencing results revealed the previously reported rare inserted duplication (p.I154_V160dup) in NaPi-IIa (12), in a homozygous state. No other potentially disease-causing mutations that could explain the phenotype were identified. Sanger sequencing verification of the p.I154_V160dup-NaPi-IIa mutation in all family members showed complete segregation with the disease phenotype (Fig. 1d) .
Haplotype analysis
To examine whether the shared p.I154_V160dup-NaPi-IIa mutation in the two apparently unrelated patients is inherited identical-by-descent from a common ancestor, we performed haplotype analysis using SNP microarray genotyping and revealed a 1.63 million bplong interval of shared homozygosity, encompassing the SLC34A1 gene locus on chromosome 5q35.3, between chromosomal positions 176,249,109 and 177,879,732, spanning 60 consecutive SNP markers (Fig. 2) .
Localization experiments
In view of the previously observed trafficking defect of the p.I154_V160dup-NaPi-IIa mutant, we hypothesized ER retention by the ER quality control machinery. To determine the intracellular localization of the p.I154_ V160dup-NaPi-IIa mutant protein, we transiently expressed WT and p.I154_V160dup mutant NaPi-IIa in epithelial cell lines and examined their colocalization with two ER resident protein markers, calnexin and the target peptide sequence, KDEL (27, 28) . As shown in Fig. 3 , although WT NaPi-IIa colocalizes with actin at the plasma membrane, the p.I154_V160dup mutant colocalizes with both KDEL and calnexin at the ER.
In vitro biochemical experiments
To study the glycosylation pattern and maturation status of WT and mutant NaPi-IIa, we subjected protein lysates from human embryonic kidney (HEK) cells transfected with S-tagged WT or p.I154_V160dup-NaPiIIa to Endo H or PNGase F digestion and resolved the treated proteins by Western blotting. As shown in Fig. 4a , incubation of WT NaPi-IIa with PNGase F caused a reduction of its molecular weight to the level of the untreated mutants, indicating that the larger size of the WT protein was attributed to N-glycosylation. Treatment of NaPi-IIa mutants with PNGase F had no impact on its molecular weight, suggesting that it was already underglycosylated. In contrast, although WT NaPi-IIa was mostly resistant to Endo H digestion, mutant NaPi-IIa exhibited Endo H sensitivity, manifested by partial digestion. The Endo H resistance of WT NaPi-IIa implies its mature glycan composition, which is mandatory for normal ER exit. In contrast, the Endo H sensitivity of mutant NaPi-IIa implies its immature state, associated with ER retention by the ER quality control machinery. Similar results were obtained with three other loss-offunction NaPi-IIa mutants harboring a trafficking defect: G153A, V408E (18) , and R495H (17) (Supplemental Fig. 1 ).
To analyze whether mutant NaPi-IIa is subject to proteasomal degradation, we incubated WT or p.I154_V160dup-NaPi-IIa-transfected HEK cells with the proteasome inhibitor, MG-132, and compared NaPiIIa levels in MG-132-treated and untreated cells by Western blotting. As shown in Fig. 4b , MG-132 exposure resulted in increased levels of p.I154_V160dup-NaPi-IIa, compared with unchanged levels of the WT product, thereby indicating that mutant NaPi-IIa is prone to proteasomal degradation and accumulates upon inhibition of the degradation machinery.
To examine a potential role for activation of ER stress response in the pathogenesis of the more generalized proximal tubulopathy associated with the p.I154_V160dup-NaPi-IIa mutation, we compared the protein level of ER stress response markers (27, 29) , in HEK cells transfected with WT NaPi-IIa, p.I154_ V160dup-NaPi-IIa, or one of three additional NaPi-IIa mutants harboring a trafficking defect under normal or phosphate-depleted conditions. Exposure of transfected cells to the ER stress inducer, tunicamycin (30) , served as a positive control. As shown (Supplemental Fig. 2) , we found no upregulation of endogenous ER stress markers in cells expressing either WT or mutant NaPi-IIa. Moreover, phosphate deprivation, as a potential trigger for enhanced NaPi-IIa expression and overwhelming of the ER-associated degradation machinery, did not induce upregulation of ER stress markers. Taken together, these results do not support activation of ER stress pathways by ER-retained NaPi-IIa mutants harboring a trafficking defect.
Discussion
In this report, we describe what, to our knowledge, are novel clinical characteristics associated with a previously reported homozygous loss-of-function mutation in NaPi-IIa (p.I154_V160dup) in two apparently unrelated and ethnically remote infants with hypercalcemia, nephrocalcinosis, renal phosphate wasting, partial proximal tubulopathy, and no evidence of rickets or CKD. This phenotype is more reminiscent of the recently described HCINF2 secondary to other NaPi-IIa mutations and differs from the clinical constellation of renal Fanconi syndrome, hypophosphatemic bone disease, and CKD (FRTS2) observed in adults with homozygosity for the p.I154_V160dup-NaPi-IIa mutation.
As opposed to the hypercalciuria observed in most reported infants with HCINF2, our currently described patients presented with normal urine calcium/creatinine ratios, although at the upper normal range for age. Of note, of 12 patients with sporadic IIH/nephrocalcinosis secondary to NaPi-IIa disruption reported by Schlingmann et al. (18) , 4 infants also exhibited absence of hypercalciuria at presentation. The absence of hypercalciuria in some infants with HCINF2 is intriguing, especially in view of the observed hypercalcemia, suppressed PTH, and nephrocalcinosis, and awaits further clarification.
The mechanisms underlying the phenotypic heterogeneity associated with NaPi-IIa disruption, in general, and with the p.I154_V160dup mutation, in particular, are unknown. The fact that one of the infants reported herein is a family member of the previously described adults with FRTS2 suggests either intrafamilial phenotypic variability or age-dependent disease progression and awaits further follow-up. Moreover, the finding of a shared mutation, inherited identical-by-descent between ethnically and geographically remote families of different genetic backgrounds, provides a unique opportunity for longitudinal study of the disease course under differential environmental and genetic modifiers.
In contrast to the renal Fanconi syndrome observed in our previously reported adults with FRTS2 and homozygosity for the p.I154_V160dup-NaPi-IIa mutation, generalized proximal tubulopathy was not described in follow-up reports on NaPi-IIa disruption (17) (18) (19) . Nevertheless, proximal tubular functional analysis in these reports was either completely lacking (18) or incomplete, omitting assessment of LMW proteinuria, uricosuria, or generalized aminoaciduria (17) . In contrast, meticulous proximal tubular assessment in the studied infants indicates partial proximal tubulopathy of early onset, showing hyperuricosuria and LMW proteinuria (Table 1) . Moreover, that exome sequencing in our previously described patients with FRTS2 excluded other disease-causing mutations as underlying their proximal tubulopathy reinforces the role of NaPi-IIa disruption in the pathogenesis of renal Fanconi syndrome. Taken together, these findings suggest that homozygous disruption of NaPi-IIa is associated with proximal tubular impairment of varying extent and severity, which may remain unnoticed or undergo age-dependent progression. The factors underlying this clinical variability are unknown.
Although the mechanism of proximal tubulopathy associated with the p.I154_V160dup-NaPi-IIa mutation is unknown, a potential explanation involves a deleterious effect exerted by intracellular accumulation of the mutant transporter on proximal tubular cell integrity. NaPi-IIa is an integral plasma membrane glycoprotein (1, 31, 32) . As such, it has been shown to undergo cotranslational folding in the ER, where it is monitored by ER quality control mechanisms (27, 31, 33, 34) according to its N-linked glycan composition, for trafficking to the brush-border membrane or to proteasomal degradation as a misfolded protein (35, 36) . In general, overproduction of misfolded proteins may overwhelm the proteasomal degradation machinery and activate ER stress response pathways, which may trigger apoptotic cell death. The results of our in vitro experiments support ER retention of the p.I154_V160dup-NaPi-IIa As indicated, kidney function of our currently reported infants was normal, both at presentation and during follow-up (Table 1) . Nevertheless, accumulating evidence suggests an increased risk for future development of CKD in these patients, given the reduced GFR in adults with the shared p.I154_V160dup-NaPi-IIa mutation (12) , combined with the observed CKD in an adolescent with NaPi-IIa impairment (19) . Moreover, recent genomewide association studies have linked SLC34A1 variants with increased susceptibility to CKD (37) (38) (39) . Although the mechanisms linking NaPi-IIa impairment with CKD are poorly understood, they may be attributed to genetic modifiers, increased susceptibility to nephrocalcinosis (19) and nephrolithiasis (9-11), or proximal tubular cell injury (40, 41) .
In accordance with accumulating clinical data on infants with HCINF2 due to various NaPi-IIa mutations, their major phenotypic features are hypercalcemia and nephrocalcinosis, whereas renal phosphate wasting and hypophosphatemia are only mild and variable. These findings suggest that, at least during infancy, the impact of NaPi-IIa dysfunction on phosphate homeostasis is variable and far exceeded by its impact on calcium metabolism. Nevertheless, as shown by us and others (12, 13, 17, 18) , the biochemical consequences of NaPi-IIa disruption may benefit from phosphate supplementation rather than from vitamin D or calcium depletion. Using an Slc34a1-knockout mouse model, Schlingmann et al. (18) elegantly deciphered the role of phosphate supplementation, as opposed to vitamin D deprivation, in restoring normal calcium and phosphate metabolism via an FGF-23-mediated mechanism, thus emphasizing the therapeutic implications of accurate molecular diagnosis of NaPi-IIa impairment. It remains to be seen whether early initiation and prolonged administration of phosphate replacement therapy may reduce the risk of long-term complications associated with NaPi-IIa disruption, including progression of nephrocalcinosis, proximal tubulopathy, or CKD.
Interestingly, the evolving story of NaPi-IIa-related clinical spectrum shares great similarity with Dent disease, which is also a proximal tubular disorder linked to a wide range of clinical phenotypes. Although Dent disease is an X-linked disorder, attributed mostly to mutations in the CLCN5 and OCRL1 genes [Dent disease 1 (MIM 300009) and Dent disease 2 (MIM 300555), respectively] on chromosome X, about 25% of patients with a Dent phenotype carry normal CLCN5 and OCRL1 genotypes, suggesting the involvement of additional genes in the pathogenesis of this disorder (42) (43) (44) . Reminiscent of NaPi-IIa-associated disease, Dent disease may also involve phenotypic combinations of varying severity and extent, including, among others, LMW proteinuria, hypercalciuria, nephrocalcinosis, nephrolithiasis, renal phosphate wasting, hypophosphatemic rickets, and progressive renal failure. In addition, Dent disease may also exhibit considerable intrafamilial variability and shows no genotype-phenotype correlation. Given the clinical overlap between Dent disease and NaPi-IIaassociated phenotypes, we postulate that some cases of sporadic Dent disease may eventually be attributed to NaPi-IIa impairment.
In summary, we have identified a previously described loss-of-function mutation in NaPi-IIa as underlying infantile hypercalcemia with partial proximal tubulopathy and have linked NaPi-IIa disruption secondary to impaired trafficking with aberrant ER retention and premature proteasomal degradation. Our findings expand the clinical spectrum of NaPi-IIa impairment and provide further evidence for the wide range of phenotypic heterogeneity associated with this disorder. Further insight into the pathogenesis of this clinical diversity may shed light on biological pathways involved in proximal tubular transport mechanisms and cell injury, as well as on the role of proximal tubular impairment in the progression of CKD.
